Related Experiment Videos

Paraneoplastic hyperpigmentation secondary to lung cancer resolving after chemotherapy

M Ozgüroğlu, V Tahan, E Ozgüroğlu

American Journal of Clinical Oncology

|October 16, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.

Actas urologicas espanolas·2024

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

ESMO open·2022

See all related articles